120 related articles for article (PubMed ID: 10556272)
1. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma.
Protheroe A; Edwards JC; Simmons A; Maclennan K; Selby P
Rheumatology (Oxford); 1999 Nov; 38(11):1150-2. PubMed ID: 10556272
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment with Rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma.
Shvidel L; Klepfish A; Berrebi A
Am J Hematol; 2001 Jul; 67(3):213-4. PubMed ID: 11391724
[No Abstract] [Full Text] [Related]
3. Anti-CD20-based therapy of B cell lymphoma: state of the art.
Kosmas C; Stamatopoulos K; Stavroyianni N; Tsavaris N; Papadaki T
Leukemia; 2002 Oct; 16(10):2004-15. PubMed ID: 12357351
[TBL] [Abstract][Full Text] [Related]
4. T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma.
Vincent-Salomon A; Mathiot C; Macintyre E; Girre V; Fourquet A; Mercier C; Fréneaux P; Dumont J; Decaudin D
Leuk Lymphoma; 2000 Apr; 37(3-4):387-91. PubMed ID: 10752990
[No Abstract] [Full Text] [Related]
5. [Monoclonal anti-CD20 antibody therapy].
Juhel L; Solal-Celigny P
Rev Prat; 2004 Apr; 54(7):711-2. PubMed ID: 15253285
[No Abstract] [Full Text] [Related]
6. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
7. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
8. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.
Takao T; Kobayashi Y; Kuroda J; Omoto A; Nishimura T; Kamitsuji Y; Fukiya E; Nakamura C; Kimura S; Yoshikawa T
Am J Hematol; 2004 Dec; 77(4):419-20. PubMed ID: 15551361
[No Abstract] [Full Text] [Related]
9. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
Grillo-López AJ; Kunkel L
Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
[No Abstract] [Full Text] [Related]
10. Anti-CD20 monoclonal antibodies: historical and future perspectives.
Lim SH; Beers SA; French RR; Johnson PW; Glennie MJ; Cragg MS
Haematologica; 2010 Jan; 95(1):135-43. PubMed ID: 19773256
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
Cheson BD; Leonard JP
N Engl J Med; 2008 Aug; 359(6):613-26. PubMed ID: 18687642
[No Abstract] [Full Text] [Related]
13. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
14. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox SJ; Goris ML; Trisler K; Negrin R; Davis T; Liles TM; Grillo-López A; Chinn P; Varns C; Ning SC; Fowler S; Deb N; Becker M; Marquez C; Levy R
Clin Cancer Res; 1996 Mar; 2(3):457-70. PubMed ID: 9816191
[TBL] [Abstract][Full Text] [Related]
16. Antibodies in the treatment of lymphoma.
Leonard JP
Clin Adv Hematol Oncol; 2004 Apr; 2(4):210-1. PubMed ID: 16163182
[No Abstract] [Full Text] [Related]
17. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
18. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
19. 1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.
Levy R
Biochim Biophys Acta; 1999 Oct; 1424(2-3):R43-4. PubMed ID: 10528154
[No Abstract] [Full Text] [Related]
20. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens.
Nordøy T; Kolstad A; Tuck MK; Aaberge IS; Husebekk A; Kaminski MS
Clin Immunol; 2001 Jul; 100(1):40-8. PubMed ID: 11414744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
